Aura Biosciences Inc (AURA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.44 (-2.28%), Market cap $0.85B, 52-week low–high $4.97 ~ $8.90.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company wa
Financial statements, price targets, institutional (13F) holdings and related news for Aura Biosciences Inc are updated in real time on BlackAll Trade.
Aura Biosciences Inc trades at $6.44 (-2.28%). Real-time quotes and charts are available on BlackAll Trade.
Aura Biosciences Inc has a market cap of about $0.85B.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors